By Counterforce Health Team in Ultomiris (ravulizumab) —

Aetna (CVS Health)'s Coverage Criteria for Ultomiris (ravulizumab) in Virginia: What Counts as "Medically Necessary"?

Quick Answer: Aetna (CVS Health) requires prior authorization for Ultomiris (ravulizumab) across all FDA-approved indications in Virginia. Submit form GR-69447 with diagnosis-specific labs, REMS compliance proof, and vaccination records. If denied, Virginia's State Corporation Commission provides free external review within 120 days. First step: Verify your coverage and gather required documentation before submitting your PA request.

Table of Contents

  1. Policy Overview
  2. Indication Requirements
  3. Step Therapy & Exceptions
  4. Quantity & Frequency Limits
  5. Required Diagnostics
  6. Site of Care & Specialty Pharmacy
  7. Evidence to Support Necessity
  8. Sample "Meets Criteria" Narrative
  9. Edge Cases
  10. Quick Reference Table
  11. Appeals Process in Virginia
  12. Common Denial Reasons & Solutions

Policy Overview

Aetna (CVS Health) maintains strict prior authorization requirements for Ultomiris (ravulizumab) across all plan types in Virginia—including commercial HMO/PPO plans, Medicare Advantage, and Medicaid managed care. The drug typically falls under the medical benefit rather than pharmacy coverage, requiring submission through CVS Specialty or your provider's portal.

Plan Types Affected:

  • Commercial PPO/HMO plans
  • Medicare Advantage (with additional CMS requirements)
  • Virginia Medicaid managed care plans
  • Self-funded employer plans administered by Aetna

All requests must use form GR-69447 and allow 30-45 days for standard decisions (72 hours for expedited reviews).

Indication Requirements

Aetna covers Ultomiris only for FDA-approved indications with specific clinical thresholds:

Paroxysmal Nocturnal Hemoglobinuria (PNH)

  • Flow cytometry showing ≥5% PNH clone in ≥2 cell lineages
  • LDH ≥1.5× upper limit of normal
  • Hemoglobin <10 g/dL with symptoms OR ≥2 transfusions in 12 months
  • Documented hemolysis despite supportive care

Atypical Hemolytic Uremic Syndrome (aHUS)

  • Thrombotic microangiopathy with thrombocytopenia, schistocytes, elevated creatinine, and elevated LDH
  • Negative Shiga toxin testing (excludes STEC-HUS)
  • ADAMTS13 activity to rule out TTP
  • May require documented eculizumab failure/intolerance

Anti-AChR+ Generalized Myasthenia Gravis (gMG)

  • Positive acetylcholine receptor antibodies
  • MG-ADL score ≥5
  • MGFA Class II-IV disease severity

AQP4+ Neuromyelitis Optica Spectrum Disorder (NMOSD)

  • Positive AQP4-IgG antibodies
  • ≥1 documented attack (optic neuritis, myelitis, etc.)
  • MRI findings consistent with NMOSD
  • Relapse despite prior immunosuppressive therapy
Note: Off-label uses require exceptional documentation and typically face higher denial rates. Stick to FDA-approved indications when possible.

Step Therapy & Exceptions

Most Aetna plans require trying eculizumab biosimilars (Bkemv, Epysqli) before approving Soliris or Ultomiris. However, exceptions exist for:

Automatic Exceptions:

  • Prior use within 365 days
  • Documented intolerance to biosimilar inactive ingredients
  • Contraindications specific to biosimilar formulations

Medical Exceptions:

  • Inadequate response to ≥26 weeks of biosimilar therapy
  • Severe adverse events attributed to biosimilar components
  • Clinical deterioration on step therapy

To document step therapy failure, include:

  • Exact dates and doses of prior therapies
  • Objective measures of inadequate response (LDH levels, transfusion requirements, MG-ADL scores)
  • Specific adverse events with timeline and severity

Counterforce Health specializes in turning these complex step therapy denials into successful appeals by identifying the specific failure criteria your case meets and drafting targeted rebuttals.

Quantity & Frequency Limits

Ultomiris dosing follows strict weight-based protocols with built-in quantity limits:

Body Weight Loading Dose Maintenance Dose Frequency
40-<60 kg 2,400 mg 3,000 mg Every 8 weeks
60-<100 kg 2,700 mg 3,300 mg Every 8 weeks
≥100 kg 3,000 mg 3,600 mg Every 8 weeks

Key Limits:

  • Maximum 6-7 infusions annually after loading dose
  • ±7 day scheduling flexibility (except first maintenance dose)
  • No concurrent complement inhibitor therapy allowed
  • Dose adjustments require new PA for quantities exceeding FDA labeling

Aetna typically approves initial authorizations for 6-12 months, requiring renewal with documented clinical benefit (LDH normalization for PNH, reduced relapse rates for NMOSD, improved MG-ADL scores for gMG).

Required Diagnostics

Each indication requires specific laboratory documentation:

Universal Requirements

  • Complete blood count with differential
  • Comprehensive metabolic panel
  • LDH level
  • Current weight for dosing calculations
  • Meningococcal vaccination records (MenACWY + MenB)

Indication-Specific Labs

PNH: Flow cytometry report, transfusion history, hemolysis markers aHUS: Platelet count, schistocyte count, creatinine, ADAMTS13 activity, complement levels gMG: AChR antibody titers, MG-ADL assessment, MGFA classification NMOSD: AQP4-IgG antibodies, MRI reports, attack frequency documentation

Tip: Labs should be current within 30-90 days of PA submission. Older results may trigger requests for updated testing.

Site of Care & Specialty Pharmacy

Aetna has specific requirements for where Ultomiris can be administered:

Preferred Sites:

  • Physician office infusion centers
  • Hospital-based ambulatory infusion units
  • Approved specialty infusion centers

Restricted/Requires Additional PA:

  • Home infusion (rarely approved)
  • Hospital inpatient administration (except for emergencies)
  • Non-contracted facilities

Specialty Pharmacy Requirements:

  • Must use CVS Specialty in most cases
  • Verify medical vs. pharmacy benefit coverage
  • Confirm deductible and copay obligations
  • Ensure cold chain handling capabilities

The drug must be ordered through approved specialty pharmacies and delivered directly to the infusion site. Patient pickup is generally not permitted due to storage requirements and REMS program restrictions.

Evidence to Support Necessity

Strong prior authorization submissions include multiple evidence types:

Primary Sources (Required)

  • FDA prescribing information for your specific indication
  • Diagnosis-specific treatment guidelines (ASH for PNH, AAN for NMOSD, etc.)
  • Clinical trial data supporting efficacy in your patient's condition

Supporting Documentation

  • Peer-reviewed studies demonstrating superiority over alternatives
  • Real-world evidence of improved outcomes
  • Economic analyses showing cost-effectiveness
  • Professional society position statements

Clinical Narrative Elements

  • Clear problem statement with ICD-10 codes
  • Detailed prior therapy history with specific failure reasons
  • Current clinical status with objective measures
  • Treatment goals with measurable outcomes
  • Monitoring plan and safety considerations

Sample "Meets Criteria" Narrative

Template Paragraph Structure:

"This 45-year-old patient with confirmed AQP4+ NMOSD (ICD-10 G36.0) meets Aetna's medical necessity criteria for Ultomiris. Laboratory confirmation shows positive AQP4-IgG antibodies (titer 1:320), and MRI demonstrates T2 hyperintense lesions in the cervical spinal cord consistent with longitudinally extensive transverse myelitis. Despite 18 months of mycophenolate mofetil 2g daily and monthly methylprednisolone pulses, the patient experienced two breakthrough relapses within the past year, including optic neuritis requiring hospitalization. Current EDSS score of 4.5 reflects significant disability progression. The patient has completed required meningococcal vaccinations (MenACWY 10/2024, MenB series completed 11/2024) and prescriber is enrolled in the Ultomiris REMS program. Weight-based dosing of 3,300mg loading dose followed by maintenance every 8 weeks aligns with FDA labeling for NMOSD prevention."

This structure addresses diagnosis confirmation, laboratory evidence, prior therapy failure, current clinical status, safety requirements, and dosing rationale in a single paragraph.

Edge Cases

Pediatric Considerations:

  • Limited data for patients <18 years
  • Requires pediatric specialist involvement
  • May need compassionate use documentation
  • Weight-based dosing adjustments

Pregnancy/Breastfeeding:

  • Category C medication requiring risk-benefit analysis
  • Maternal-fetal medicine consultation recommended
  • Enhanced monitoring requirements
  • Potential REMS modifications

Comorbidities:

  • Active infections may delay initiation
  • Immunocompromised patients need additional monitoring
  • Concurrent complement disorders require specialist evaluation
  • Renal impairment may affect dosing intervals

Escalation Paths:

  • Peer-to-peer review with medical director
  • Independent medical review for complex cases
  • Compassionate use programs for exceptional circumstances
  • Clinical trial enrollment consideration

Quick Reference Table

Requirement What It Means Where to Find It Source
Prior Authorization Form GR-69447 required Aetna provider portal PA Form
REMS Enrollment Prescriber must enroll ultsolrems.com REMS Site
Vaccination MenACWY + MenB ≥2 weeks prior CDC ACIP guidelines Vaccination Guide
Step Therapy May require eculizumab trial Plan-specific formulary Coverage Policy
Site of Care Office/ambulatory preferred Infusion policy Site Guidelines
Appeal Deadline 180 days from denial Member handbook Plan documents
External Review 120 days after final denial Virginia SCC VA External Review

Appeals Process in Virginia

Virginia provides robust appeal rights through the State Corporation Commission (SCC) Bureau of Insurance:

Internal Appeals (Aetna)

  1. Standard Appeal: Submit within 180 days via provider portal or fax 1-800-982-5706
  2. Expedited Appeal: For urgent cases, 72-hour decision timeline
  3. Peer-to-Peer: Request medical director review before formal appeal

Virginia External Review

After exhausting internal appeals, Virginia residents can file for independent external review:

Timeline: 120 days from final internal denial Cost: Free to patients Process: Submit Form 216-A to SCC Bureau of Insurance Decision Time: 45 days standard, 72 hours expedited Contact: 1-877-310-6560 or [email protected]

The SCC assigns cases to independent review organizations (IROs) with relevant clinical expertise. IRO decisions are binding on insurers and have successfully overturned many specialty drug denials in Virginia.

From Our Advocates: "We've seen Virginia patients succeed in external review by emphasizing the FDA approval status and providing clear documentation of prior therapy failures. One composite case involved an NMOSD patient who was initially denied due to 'experimental' classification, but the IRO overturned this after reviewing FDA labeling and clinical trial data showing established efficacy."

Common Denial Reasons & Solutions

Denial Reason How to Overturn Key Documents
"Experimental/Investigational" Cite FDA approval date and indication FDA Label
"Step therapy not completed" Document biosimilar failure/intolerance Prior therapy records, adverse event reports
"Not medically necessary" Provide clinical evidence and guidelines Treatment guidelines, peer-reviewed studies
"Dosing exceeds guidelines" Reference FDA weight-based table Prescribing information, patient weight
"Site of care not appropriate" Justify medical need for specific setting Clinical complexity documentation
"REMS not completed" Submit enrollment and vaccination proof REMS certificates, immunization records

Counterforce Health helps patients and providers navigate these common denial patterns by creating evidence-based appeals that directly address each payer's specific concerns and criteria.

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage policies change frequently, and individual circumstances vary. Always verify current requirements with Aetna directly and consult healthcare providers for medical decisions.

Need Help? Contact Virginia's State Corporation Commission Bureau of Insurance at 1-877-310-6560 for free assistance with insurance appeals and external review processes.

Sources & Further Reading

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.